Trials / Completed
CompletedNCT04099641
An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients
A Phase 2, Multicenter Open-label, Non-randomized Study of Bavituximab Plus Pembrolizumab in Patients With Advanced Gastric or Gastroesophageal Cancer Who Have Progressed on or After at Least One Prior Standard Therapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (actual)
- Sponsor
- OncXerna Theraputics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the combination of bavituximab and pembrolizumab in the treatment of gastric and gastroesphogeal cancer. All patients will receive both bavituximab, a drug that is not yet approved by the FDA, and pembrolizumab known as Keytruda. There is no expanded access program available for the investigational agents per this protocol.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bavituximab | Bavituximab IV infusion |
| DRUG | Pembrolizumab Injection | Pembrolizumab IV Infusion |
Timeline
- Start date
- 2019-09-11
- Primary completion
- 2021-12-20
- Completion
- 2022-10-26
- First posted
- 2019-09-23
- Last updated
- 2023-02-08
- Results posted
- 2023-02-08
Locations
21 sites across 4 countries: United States, South Korea, Taiwan, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04099641. Inclusion in this directory is not an endorsement.